AstraZeneca Pharma India Receives NPPA Demand Notice Over Alleged Overcharging for Symbicort Turbuhaler
AstraZeneca Pharma India Limited has received a demand notice from the National Pharmaceutical Pricing Authority (NPPA) regarding alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The NPPA issued the notice concerning the pricing of Symbicort Turbuhaler 160/4.5 (Inhaler).The demand notice was received by AstraZeneca on July 29, 2026. It pertains to alleged overcharging for the product during the period spanning May 2016 to November 2025.
The NPPA has demanded a payment of Rs. 1,48,65,83,590/-, which includes interest calculated up to August 20, 2026.
Financial details and the nature of the action are summarized below:
| Particulars | Details |
|---|---|
| Authority Name | National Pharmaceutical Pricing Authority (NPPA) |
| Alleged Violation | Overcharging under DPCO, 2013 |
| Product Concerned | Symbicort Turbuhaler 160/4.5 (Inhaler) |
| Period of Allegation | May 2016 to November 2025 |
| Demand Amount (including interest) | Rs. 1,48,65,83,590/- |
| Date of Receipt | July 29, 2026 |
Following the receipt of the demand notice from NPPA, AstraZeneca Pharma India Limited is currently evaluating the matter and exploring appropriate legal actions in response to the allegations.
ASTRAZEN Stock Price Movement
On Thursday, shares of AstraZeneca Pharma India Limited shed value, settling at ₹8094.5 after slipping by 0.92%. The equity saw a reported trading volume of 1629 shares during the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.